Exelixis Inc
EXEL: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$42.50 | Kps | Fbpwqxnd |
Exelixis Reports Q2 Results in Line With Expectations; Maintaining $18.90 FVE, Shares Fairly Valued
Exelixis reported solid second-quarter results highlighted by revenue of $419 million, representing a 9% increase from the prior-year period thanks to strong performance of its cabozantinib franchise. Exelixis is tracking our expectations, and management reiterated its 2022 guidance. We maintain our fair value estimate of $18.90 per share, no-moat rating, and stable moat trend. We view shares as fairly valued, currently trading in 3-star territory.